Major Facilities

RFA 07-03: CIRM Major Facilities Grant Program

The mission of CIRM is ”To support and advance stem cell research and regenerative medicine under the highest ethical and medical standards for the discovery and development of cures, therapies, diagnostics and research technologies to relieve human suffering from chronic disease and injury”

In support of this mission, CIRM has adopted a Scientific Strategic Plan that serves as a blueprint for guiding CIRM’s plans to partner with research institutions in California in creating robust stem cell programs that span basic, translational and clinical research. A key aspect of the Scientific Strategic Plan is the investment in research facilities. The Plan states that new facilities will be needed to (1) accommodate the increase in researchers engaged in stem cell research in California as a result of CIRM’s research grant and training programs, and (2) provide research space that would otherwise not be available due to federal government restrictions on certain kinds of stem cell research.

This Major Facilities Grant Program will fund the establishment of CIRM facilities to support stem cell research programs that encompass all or part of the spectrum of research that will lead from discovery to development and testing of cures, therapies, diagnostics and technologies for the treatment of injury or disease. Part One of the application will address the breadth and depth of the stem cell research program at the applicant institution(s) seeking facilities funding, and the relationship of the proposed major facility to that program. If CIRM’s governing body, the Independent Citizens Oversight Committee (ICOC), approves all or part of an institution’s Part One application, then the institution(s) will be invited in Part Two of the application to apply for one of three levels of funding, and in that application to address the technical aspects of its building program, to explain how that the program aligns with CIRM’s objectives, and why that program represents a good value for California taxpayers’ investment.

ICOC approval: 
May 7, 2008

© 2013 California Institute for Regenerative Medicine